Page last updated: 2024-12-04

betahistine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Betahistine: A histamine analog and H1 receptor agonist that serves as a vasodilator. It is used in MENIERE DISEASE and in vascular headaches but may exacerbate bronchial asthma and peptic ulcers. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

betahistine : An aminoalkylpyridine that is pyridine substituted by a 2-(methylamino)ethyl group at position 2. It acts as a histamine agonist and a vasodilator, and is thought to improve the microcirculation of the labyrinth, resulting in reduced endolymphatic pressure. It is used (generally as the hydrochloride or mesylate salt) to reduce the symptoms of vertigo, tinnitus, and hearing loss associated with Meniere's disease. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2366
CHEMBL ID24441
CHEBI ID35677
SCHEMBL ID125582
MeSH IDM0002430

Synonyms (141)

Synonym
methyl[2-(pyridin-2-yl)ethyl]amine
BRD-K91315211-334-02-3
BRD-K91315211-300-02-4
smr000059096
2-(2-methylaminoethyl)pyridine
MLS000028903
pyridine, 2-(2-methylaminoethyl)-
[2-(2-pyridyl)ethyl]methylamine
pt 9 base
2-[2-(methylamino)ethyl]pyridine
5638-76-6
2-pyridineethanamine, n-methyl-
vasomotal
pyridine, 2-[2-(methylamino)ethyl]-
serc base
nsc-42617
nsc42617
n-methyl-2-pyridineethylamine
betahistine
sinmenier (free base)
KBIO1_000602
DIVK1C_000602
n-methyl-2-pyridin-2-ylethanamine
betahistinum
2-(beta-methylaminoethyl)pyridine
n-methyl-2-(2-pyridinyl)ethanamine
n-methyl-2-pyridineethanamine
CHEBI:35677 ,
betahistina
SPECTRUM_000274
beta-histine
pyridine, 2-(2-(methylamino)ethyl)-
betahistinum [inn-latin]
betahistine [inn:ban]
brn 0112294
nsc 42617
2-(2-(methylamino)ethyl)pyridine
betahistina [inn-spanish]
(2-(2-pyridyl)ethyl)methylamine
n-methyl-n-beta-(2-pyridyl)ethylamine
betaistina [dcit]
einecs 227-086-4
IDI1_000602
betahistine (inn)
vestibo (tn)
D07522
BPBIO1_000645
BSPBIO_003410
PRESTWICK3_000543
BSPBIO_000585
SPECTRUM5_001393
PRESTWICK2_000543
AB00053577
2-(2-methylaminoethyl)pyridine, 97%
methyl-(2-pyridin-2-yl-ethyl)-amine
KBIO3_002630
KBIO2_000754
KBIO2_003322
KBIOSS_000754
KBIOGR_000688
KBIO2_005890
SPECTRUM2_001191
SPECTRUM3_001735
PRESTWICK1_000543
SPECTRUM4_000254
NINDS_000602
SPBIO_001261
PRESTWICK0_000543
SPBIO_002506
NCGC00093362-02
NCGC00093362-03
CHEMBL24441 ,
DB06698
AKOS000255727
FT-0669217
STK801447
n-methyl-2-(pyridin-2-yl)ethanamine
BBL004908
n-methyl-n-(2-pyridin-2-ylethyl)amine
x32kk4201d ,
betaistina
ec 227-086-4
unii-x32kk4201d
n-methyl-n-[2-(2-pyridyl)ethyl]amine
FT-0622910
PS-4217
cid_203875
bdbm96589
n-methyl-2-pyridin-2-yl-ethanamine;hydrochloride
methyl-[2-(2-pyridyl)ethyl]amine;hydrochloride
n-methyl-2-(2-pyridinyl)ethanamine;hydrochloride
histalean
betahistine [inn]
betahistine [vandf]
vestibo
betahistine [mart.]
betahistine [who-dd]
betahistine [mi]
S5619
AR1013
betahistine dihdrochloride
methyl(2-pyridinyl)ethylamine
(2-methylaminoethyl)pyridine
2-(2-methylaminoethyl) pyridine
n-methyl-2-pyridin-2-ylethaneamine
2-[2-(n-methylamino)ethyl]pyridine
2-(2(methylamino)ethyl)pyridine
methyl-(2-pyridin-2-ylethyl)amine
methyl-(2-pyridin-2-yl-ethyl)amine
2-(2-methylamino-ethyl)-pyridine
n-methyl-2-(pyridine-2-yl)ethanamine
SCHEMBL125582
Q-200707
2-(.beta.-methylaminoethyl)pyridine
n-methyl-2-(2-pyridinyl)ethanamine #
.beta.-histine
n-methyl-n-.beta.-(2-pyridyl)ethylamine
AB00053577_13
AB00053577_12
DTXSID3022665
EX-A921
mfcd00006362
HY-B0524
CS-0009496
SBI-0051588.P003
5638-76-6 (free base)
F2158-0901
BCP16849
akos bbs-00002883
Q368995
obe101
EN300-17834
SB17406
HMS3886O12
CCG-266132
SB37365
ethyl nipicotate
n-methyl-2-(pyridin-2-yl)ethan-1-amine
betahistine free base
2-(methylaminoethyl)pyridine
gtpl11937

Research Excerpts

Overview

Betahistine is a histamine-like drug that is used in the treatment of Ménière's disease. Betahistine may reduce olanzapine's effect on histamine receptors in the brain.

ExcerptReferenceRelevance
"Betahistine is a clinical medication for the treatment of benign paroxysmal positional vertigo (BPPV). "( Betahistine alleviates benign paroxysmal positional vertigo (BPPV) through inducing production of multiple CTRP family members and activating the ERK1/2-AKT/PPARy pathway.
Hui, J; Ji, Z; Lei, Q; Zi, D, 2022
)
3.61
"Betahistine is a weak agonist for histamine H1 receptors and strong antagonist for histamine H3 receptors."( [Betahistine in vestibular disorders: current concepts and perspectives].
Amelin, AV; Guseva, AL; Kunelskaya, NL; Lilenko, SV; Lyapin, AV; Melnikov, OA; Samartcev, IN; Voronov, VA; Zamergrad, MV; Zaytseva, OV, 2021
)
2.25
"Betahistine is a histamine analogue that is used for the treatment of Menière's disease. "( Role of capillary pericytes and precapillary arterioles in the vascular mechanism of betahistine in a guinea pig inner ear model.
Bertlich, M; Canis, M; Freytag, S; Ihler, F; Jakob, M; Strupp, M; Weiss, BG, 2017
)
2.12
"Betahistine is a histamine-like drug that is used in the treatment of Ménière's disease. "( Betahistine metabolites, aminoethylpyridine, and hydroxyethylpyridine increase cochlear blood flow in guinea pigs in vivo.
Bertlich, M; Canis, M; Ihler, F; Sharaf, K; Strupp, M; Weiss, BG, 2014
)
3.29
"Betahistine is a histamine-like drug that is considered beneficial in Ménière's disease by increasing cochlear blood flow. "( Histaminergic H3-Heteroreceptors as a Potential Mediator of Betahistine-Induced Increase in Cochlear Blood Flow.
Bertlich, M; Canis, M; Freytag, S; Ihler, F; Strupp, M; Weiss, BG, 2015
)
2.1
"Betahistine is a centrally acting histamine-H1 agonist, and therefore may reduce olanzapine's effect on histamine receptors in the brain."( Betahistine decreases olanzapine-induced weight gain and somnolence in humans.
Albeck, JH; Barak, N; Beck, Y, 2016
)
2.6
"Betahistine is a drug that may work by improving blood flow to the inner ear."( Betahistine for symptoms of vertigo.
Hussain, K; Murdin, L; Schilder, AG, 2016
)
2.6
"Betahistine is a medicine used to treat vestibular disorders that has also been used to treat tinnitus."( Betahistine in the treatment of tinnitus in patients with vestibular disorders.
Caovilla, HH; Ganança, CF; Ganança, FF; Ganança, MM; Gazzola, JM,
)
3.02
"Betahistine is a histamine H(1)-receptor agonist and H(3)-receptor antagonist that is administered to treat Menière's disease. "( Betahistine exerts a dose-dependent effect on cochlear stria vascularis blood flow in guinea pigs in vivo.
Bertlich, M; Canis, M; Ihler, F; Sharaf, K; Strieth, S; Strupp, M, 2012
)
3.26
"Betahistine is a structural analogue of histamine that is prescribed for the treatment of vestibular disorders such as Ménière's disease and the symptomatic treatment of vertigo. "( Betahistine: a retrospective synopsis of safety data.
Jeck-Thole, S; Wagner, W, 2006
)
3.22
"Betahistine is an orally administered, centrally acting histamine H(1) receptor agonist with partial H(3) antagonistic activity and no H(2)-binding effects. "( Betahistine: what's new on the agenda?
Barak, N, 2008
)
3.23
"Betahistine is a cerebral vasodilator structurally related to histamine, which stimulates H1 bronchial and vascular receptors. "( Betahistine-induced bronchospasm.
Antón, E; Jerez, J; Jiménez, I; Picáns, I, 1996
)
3.18
"Betahistine, which is a weak agonist at the H1 receptor and a moderate antagonist at the presynaptic H3 autoreceptor, weakly excites medial vestibular nucleus cells but antagonizes their responses to histamine."( Betahistine, vestibular function and compensation: in vitro studies of vestibular function and plasticity.
Dutia, MB, 2000
)
2.47

Effects

Betahistine (BH) has been used widely to treat cochlear disorders, such as tinnitus and Meniere's disease. Betahistine has H₃ receptor antagonistic effects to increase histamine release, which may augment its direct agonistic effects on H⁁ receptors.

ExcerptReferenceRelevance
"Betahistine has a dose-dependent effect on the increase of blood flow in cochlear capillaries. "( Betahistine exerts a dose-dependent effect on cochlear stria vascularis blood flow in guinea pigs in vivo.
Bertlich, M; Canis, M; Ihler, F; Sharaf, K; Strieth, S; Strupp, M, 2012
)
3.26
"Betahistine has not been proven to be superior to placebo in the BEMED study, a multicenter, double-blind, randomized, placebo controlled trial. "( Betahistine Prescribing Practices in England: An Analysis of Prescribing and National Spending Pre- and Post-BEMED Trial.
Ghedia, R; Harcourt, J; Sutton, L, 2023
)
3.8
"Betahistine has been used to reduce intensity and frecuency of vertigo attacks, but there is controversy regarding its effectiveness."( Is betahistine effective for Ménière’s disease?
Rosenbaum, A; Winter, M, 2017
)
1.8
"Betahistine has H₃ receptor antagonistic effects to increase histamine release, which may augment its direct agonistic effects on H₁ receptors."( Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model.
Deng, C; Huang, XF; Lian, J; Pai, N, 2012
)
1.34
"Betahistine has a dose-dependent effect on the increase of blood flow in cochlear capillaries. "( Betahistine exerts a dose-dependent effect on cochlear stria vascularis blood flow in guinea pigs in vivo.
Bertlich, M; Canis, M; Ihler, F; Sharaf, K; Strieth, S; Strupp, M, 2012
)
3.26
"Betahistine (BH) has been used widely to treat cochlear disorders, such as tinnitus and Meniere's disease. "( Betahistine-induced vascular effects in the rat cochlea.
Grénman, R; Kallinen, J; Laurikainen, EA; Miller, JM; Nuttall, AL; Quirk, WS; Ren, T; Virolainen, E, 1993
)
3.17
"Betahistine which has both H(3)-antagonistic activity and H(1)-agonistic activity significantly reduced ADD, albeit mild at a toxic dose, though seizure ranks were not affected."( Lack of substantial effect of the H(3)-antagonist thioperamide and of the non-selective mixed H(3)-antagonist/H(1)-agonist betahistine on amygdaloid kindled seizures.
Noguchi, E; Tsuru, N; Yoshida, M, 2000
)
1.24
"Betahistine has been used to treat several vestibular disorders of both central and peripheral origin. "( Betahistine produces post-synaptic inhibition of the excitability of the primary afferent neurons in the vestibular endorgans.
Benvenuti, C; Chávez, H; Soto, E; Valli, P; Vega, R, 2001
)
3.2
"Betahistine has been used to treat several vestibular disorders of both central and peripheral origin. "( Action mechanism of betahistine in the vestibular end organs.
Benvenuti, C; Chávez, H; Guth, PS; Mira, E; Soto, E; Valli, P; Vega, R, 2001
)
2.08

Actions

ExcerptReferenceRelevance
"Betahistine did not produce an effect on food intakes or appetites. "( Acute effects of betahistine hydrochloride on food intake and appetite in obese women: a randomized, placebo-controlled trial.
Akomeah, A; Ali, AH; Barak, N; Brady, SM; Calis, KA; Courville, A; Crocker, MK; Kozlosky, M; Reynolds, JC; Stern, EA; Yanoff, LB; Yanovski, JA, 2010
)
2.14

Treatment

Betahistine treatment improved quality of life, was safe and well-tolerated by Indian patients suffering from vertigo. Betahistine co-treatment can reduce food intake and increase the effect of thermogenesis in brown adipose tissue.

ExcerptReferenceRelevance
"Betahistine add-on treatment in posterior benign paroxysmal positional vertigo resulted in improvements in both visual analog scale score and dizziness handicap inventory."( Betahistine add-on therapy for treatment of subjects with posterior benign paroxysmal positional vertigo: a randomized controlled trial.
Cirak, M; Gunes, S; Koç, RH; Sayin, I; Temirbekov, D; Yazici, ZM,
)
2.3
"Betahistine treatment improved quality of life, was safe and well-tolerated by Indian patients suffering from vertigo."( Efficacy of Betahistine by Patient-Reported Outcomes and its Tolerability Profile in Indian Patients with Vestibular Vertigo.
Biswas, A; Kirtane, MV, 2017
)
1.56
"Betahistine co-treatment can reduce food intake and increase the effect of thermogenesis in brown adipose tissue by modulating hypothalamic H1R-NPY-AMPKα (NPY: neuropeptide Y; AMPKα: AMP-activated protein kinase α) pathways, and ameliorate olanzapine-induced dyslipidaemia through modulation of AMPKα-SREBP-1-PPARα-dependent pathways (SREBP-1: Sterol regulatory element binding protein 1; PPARα: Peroxisome proliferator-activated receptor-α) in the liver."( Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications.
Deng, C; Huang, XF; Lian, J; Pai, N, 2016
)
1.41
"Betahistine treatment attenuated the severity of arthritis and reduced the levels of pro-inflammatory cytokines, including TNF-α, IL-6, IL-23 and IL-17A, in the paw tissues of CIA mice."( Betahistine attenuates murine collagen-induced arthritis by suppressing both inflammatory and Th17 cell responses.
Chao, YH; Chen, DY; Chen, YM; Li, YR; Lim, YP; Lin, CC; Tang, KT; Yang, DH, 2016
)
2.6
"Betahistine treatment added to VR was effective in increasing postural stability."( Does betahistine treatment have additional benefits to vestibular rehabilitation?
Akyuz, A; Bilgen, C; Celebisoy, N; Eyigor, S; Gode, S; Karapolat, H; Kirazli, T; Kirazli, Y, 2010
)
1.6
"Betahistine treatment alone had no effect on weight gain and food intake."( Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model.
Deng, C; Huang, XF; Lian, J; Pai, N, 2012
)
1.34
"Betahistine treatment also resulted in marked authentic (p<0,05) improvement of stabilometric parameters in biological feedback task that might be explained by activation of the mechanisms maintaining vertical balance."( [Clinico-neurological and stabilometric analysis of betahistine (betaserc) efficacy in the patients with vertigo in the rehabilitation period of ischemic stroke].
Galanov, DV; Gekht, AB; Vialkova, AB, 2005
)
1.3
"Betahistine is used for treatment of several vestibular disorders. "( Betahistine increases vestibular blood flow.
Dziadziola, JK; Laurikainen, EL; Quirk, WS; Rachel, JD, 1999
)
3.19
"Betahistine treatment induced symmetrical changes with up-regulation of histidine decarboxylase mRNA in the tuberomammillary nucleus and reduction of [(3)H]N-alpha-methylhistamine labeling in both the tuberomammillary nucleus, the vestibular nuclei complex and nuclei of the inferior olive."( Betahistine dihydrochloride interaction with the histaminergic system in the cat: neurochemical and molecular mechanisms.
Chotard, C; Lacour, M; Mourre, C; Tighilet, B; Trottier, S, 2002
)
2.48
"The treatment with betahistine reduced the intensity and duration of vertigo, led to improvement of coordination and equilibrium, increase stability of a vertical posture that was accompanied by significant (p<0,05) improvement of the values on the Hoffenberth and Bohannon scales."( [Clinico-neurological and stabilometric analysis of betahistine (betaserc) efficacy in the patients with vertigo in the rehabilitation period of ischemic stroke].
Galanov, DV; Gekht, AB; Vialkova, AB, 2005
)
0.9

Toxicity

The fixed combination of cinnarizine and dimenhydrinate is a safe and potentially superior treatment option for patients suffering from central and/or peripheral vestibular vertigo. There were no serious adverse events reported in the study, betahistine was safe and well tolerated at all the dose levels tested.

ExcerptReferenceRelevance
" Until 31 December 2005, 554 adverse drug reaction (ADR) reports with 994 individual signs and symptoms were received by the marketing authorisation holder from worldwide sources and were reviewed and evaluated."( Betahistine: a retrospective synopsis of safety data.
Jeck-Thole, S; Wagner, W, 2006
)
1.78
"Sanchi Tong Shu capsule is a safe and effective drug for the treatment of common aural vertigo."( [Clinical effectiveness and safety of sanchi tong shu capsule in the treatment of aural vertigo: a multi-center randomized controlled clinical trial].
Hu, G; Kong, W; Li, X; Liu, B; Liu, S; Meng, J; Yang, Y, 2012
)
0.38
" There were no serious adverse events reported in the study, betahistine was safe and well tolerated at all the dose levels tested."( Safety, tolerability and pharmacokinetics of 2-pyridylacetic acid, a major metabolite of betahistine, in a phase 1 dose escalation study in subjects with ADHD.
Desai, PB; Gabbita, P; Moorthy, G; Sallans, L; Sallee, F; Zemlan, F, 2015
)
0.88
" Betahistine, a structural analogue of histamine and presumably the most widely prescribed anti-vertigo drug worldwide, has previously been shown to be an effective and safe treatment for these patients."( Efficacy and Safety of a Fixed Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg vs Betahistine Dihydrochloride 16 mg in Patients with Peripheral Vestibular Vertigo: A Prospective, Multinational, Multicenter, Double-Blind, Randomized, Non-inferior
Hahn, A; Kunelskaya, N; Medzhidieva, D; Paschinin, A; Ryazantsev, SV; Scholtz, AW; Schumacher, K; Stefflova, B; Weisshaar, G, 2019
)
1.64
"92%) reported 13 non-serious adverse events; 2 cinnarizine/dimenhydrinate-treated patients discontinued the study prematurely due to adverse events as compared to 5 betahistine-treated patients."( Efficacy and Safety of a Fixed Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg vs Betahistine Dihydrochloride 16 mg in Patients with Peripheral Vestibular Vertigo: A Prospective, Multinational, Multicenter, Double-Blind, Randomized, Non-inferior
Hahn, A; Kunelskaya, N; Medzhidieva, D; Paschinin, A; Ryazantsev, SV; Scholtz, AW; Schumacher, K; Stefflova, B; Weisshaar, G, 2019
)
0.93
"9%) reported 75 non-serious adverse events (AEs), and 19 patients (2."( Efficacy and Safety of a Fixed-Dose Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg in the Treatment of Patients with Vestibular Vertigo: An Individual Patient Data Meta-Analysis of Randomised, Double-Blind, Controlled Clinical Trials.
Hampel, R; Scholtz, AW; Waldfahrer, F; Weisshaar, G, 2022
)
0.72
"The findings of the present meta-analysis indicate that the fixed combination of cinnarizine and dimenhydrinate is a safe and potentially superior treatment option for patients suffering from central and/or peripheral vestibular vertigo, as compared to current standard treatments such as cinnarizine, dimenhydrinate or betahistine given alone in monotherapy."( Efficacy and Safety of a Fixed-Dose Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg in the Treatment of Patients with Vestibular Vertigo: An Individual Patient Data Meta-Analysis of Randomised, Double-Blind, Controlled Clinical Trials.
Hampel, R; Scholtz, AW; Waldfahrer, F; Weisshaar, G, 2022
)
0.89
"Tandem Romberg test (TRT) for primary efficacy, standing on foam, tandem gait, subjective visual vertical and spontaneous nystagmus for secondary efficacy, Vestibular Rehabilitation Benefit Questionnaire (VRBQ) for exploratory efficacy; nasal symptoms and adverse events for safety."( Efficacy and Safety of Intranasal Betahistine in the Treatment of Surgery-Induced Acute Vestibular Syndrome: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Study.
Betka, J; Chovanec, M; Devèze, A; Giannuzzi, AL; Krempaská, S; Meyer, T; Przewoźny, T; Scheich, M; Strupp, M; Van de Heyning, P; Van Rompaey, V, 2023
)
1.19

Pharmacokinetics

Plasma levels of 2-pyridylacetic acid (2-PAA), a major metabolite of betahistine were quantified using a validated LC-MS/MS method. The validated method was successfully applied to a pharmacokinetic study ofbetahistine in healthy volunteers.

ExcerptReferenceRelevance
" The validated method was successfully applied to a pharmacokinetic study of betahistine in healthy volunteers."( LC-MS-MS analysis of 2-pyridylacetic acid, a major metabolite of betahistine: application to a pharmacokinetic study in healthy volunteers.
Chen, XY; Duan, JL; Yan, BX; Zhong, DF, 2003
)
0.79
" Plasma levels of 2-pyridylacetic acid (2-PAA), a major metabolite of betahistine were quantified using a validated LC-MS/MS method and used for pharmacokinetic analysis and dose proportionality of betahistine."( Safety, tolerability and pharmacokinetics of 2-pyridylacetic acid, a major metabolite of betahistine, in a phase 1 dose escalation study in subjects with ADHD.
Desai, PB; Gabbita, P; Moorthy, G; Sallans, L; Sallee, F; Zemlan, F, 2015
)
0.87

Compound-Compound Interactions

This study aims to investigate the effect of nimodipine combined with betahistine on the levels of CRP and other inflammatory cytokines, as well as vascular endothelial function in patients with hypertensive cerebral vasospasm.

ExcerptReferenceRelevance
"To evaluate the therapeutic efficacy of Yinxing Damo (YXDM) combined with Betahistine Hydrochloride Injection (BHI) on vertebra basilar artery ischemic vertigo (VBIV)."( [A clinical study on the effect of Yinxing Damo combined with betahistine hydrochloride injection on vertebral basilar artery ischemic vertigo].
Deng, GB; Deng, Y; Tan, C; Zhu, HQ, 2005
)
0.8
"YXDM combined with BHT injection had better effect in treating patients with VBIV is an ideal drug for VBIV."( [A clinical study on the effect of Yinxing Damo combined with betahistine hydrochloride injection on vertebral basilar artery ischemic vertigo].
Deng, GB; Deng, Y; Tan, C; Zhu, HQ, 2005
)
0.57
"This study aims to investigate the effect of nimodipine combined with betahistine on the levels of CRP and other inflammatory cytokines, as well as vascular endothelial function in patients with hypertensive cerebral vasospasm."( Effects of nimodipine combined with betahistine on CRP and other inflammatory cytokines and vascular endothelial function in patients with hypertensive cerebral vasospasm.
Liu, X; Luo, X; Sheng, P; Wang, Y; Xiao, P; Zeng, K; Zhao, N, 2020
)
1.07
" The current study will carry out a widespread systematic review to estimate clinical therapeutic effects of gastrodin in combination with betahistine on vertigo."( Clinical therapeutic effects of gastrodin in combination with betahistine on vertigo: A protocol for systematic review and meta-analysis.
Jin, S; Liu, F; Qiao, YL; Xiang, WQ, 2021
)
1.06
"The current study aims to stipulate more consistent substantiation to explore whether gastrodin combined with betahistine is more effective for the treatment of vertigo."( Clinical therapeutic effects of gastrodin in combination with betahistine on vertigo: A protocol for systematic review and meta-analysis.
Jin, S; Liu, F; Qiao, YL; Xiang, WQ, 2021
)
1.07
"Low dose betahistine increased cochlear microcirculation significantly when combined with selegiline."( Low Dose Betahistine in Combination With Selegiline Increases Cochlear Blood Flow in Guinea Pigs.
Bertlich, M; Canis, M; Freytag, S; Ihler, F; Kloos, B; Lauer, SK; Spiegel, JL; Weiss, BG, 2023
)
1.74

Bioavailability

ExcerptReferenceRelevance
"To assess the comparative bioavailability of two formulations (16 mg tablet) of betahistine (CAS 5579-84-0) in healthy volunteers of both sexes."( Comparative bioavailability of betahistine tablet formulations administered in healthy subjects.
Chen, LS; De Nucci, G; Mendes, GD; Val, L, 2010
)
0.87
" Finally, drug bioavailability of the BH."( Transbuccal delivery of betahistine dihydrochloride from mucoadhesive tablets with a unidirectional drug flow: in vitro, ex vivo and in vivo evaluation.
Aboud, HM; Ali, AA; El-Nabarawi, MA; Godah, AH; Hassan, AH, 2016
)
0.74
"2HCl-optimized buccal mucoadhesive formulation showed percentage relative bioavailability of 177%."( Transbuccal delivery of betahistine dihydrochloride from mucoadhesive tablets with a unidirectional drug flow: in vitro, ex vivo and in vivo evaluation.
Aboud, HM; Ali, AA; El-Nabarawi, MA; Godah, AH; Hassan, AH, 2016
)
0.74

Dosage Studied

The daily dosage of 48 mg of betahistine during 120 consecutive days is useful to reduce or eliminate tinnitus in patients with vestibular disorders. The achievement of the same clinical effect with a significantly lower (about 1/5) dosage ofbetahistine can be explained by the inhibition of the MAO-B by selegiline.

ExcerptRelevanceReference
" Thirty received betahistine hydrochloride (SERC) or placebo orally in fixed dosage for six months on a double-blind basis and were followed by ward behavioral and psychometric ratings."( Rheoencephalographic and other studies of betahistine in humans. IV. Prolonged administration with improvement in arteriosclerotic dementia.
Blatchley, RJ; Bohm, M; Fisher, R; Floam, J; Seipel, JH,
)
0.74
" These results suggest a significant cumulative effect in reducing infarct size over that achieved with one agent alone; however, further studies are needed to determine the appropriate dosage and temporal factors."( Reduction of experimental myocardial infarct size by combined treatment with methylprednisolone sodium succinate and betahistine hydrochloride.
Joyce, LD; Lillehei, RC; Mauer, HG; Smith, JM, 1978
)
0.47
" Betahistidine was given in an average dosage of 4 mg three times daily."( [Betahistidine hydrochloride in the treatment of vertebro-basilar insufficiency].
Botez, MI, 1975
)
0.25
" The proposed procedures were applied successfully for the determination of the two investigated drugs in their tablets dosage form."( Utilization of carbon disulphide for the analytical determination of betahistine hydrochloride and captopril in their pharmaceutical preparations.
Bakry, RS; Belal, SF; El Walily, AF; Razak, OA, 1999
)
0.54
" The betahistine dosage was 16 mg twice per day for 3 months."( Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo.
Brizi, S; Fattori, B; Frasconi, P; Ghilardi, L; Guidetti, G; Leprini, M; Maiolino, L; Malannino, N; Mira, E; Mora, R; Nuti, D; Ottoboni, S; Pagnini, P; Pallestrini, E; Passali, D; Russolo, M; Simoncelli, C; Tirelli, G; Vicini, C, 2003
)
2.28
" The duration of treatment (6-8 weeks) and dosage were comparable in all studies."( Treatment of vertigo with a homeopathic complex remedy compared with usual treatments: a meta-analysis of clinical trials.
Klein, P; Schneider, B; Weiser, M, 2005
)
0.33
" The lowest dose (2 mg/kg) given the longest time (3 months) was close to the dosage for vestibular defective patients."( Dose- and duration-dependent effects of betahistine dihydrochloride treatment on histamine turnover in the cat.
Lacour, M; Tighilet, B; Trottier, S, 2005
)
0.6
" High efficacy of betaserk used during 2 months in dosage 16 mg three times a day was demonstrated by improvement of the patient's state in 97% cases."( [Epidemiology, clinical features and betaserc therapy of vertigo in initial and reversible cerebrovascular pathology].
Alekseeva, NS; Chechetkin, AO; Fedin, PA; Gornostaeva, GV; Prokopovich, ME; Varakin, IuIa, 2005
)
0.33
"Despite the considerable limitations of an open, non-masked trial, particularly in Menière's disease (MD), a higher dosage of betahistine-dihydrochloride and a long-term treatment seems to be more effective than a low dosage and short-term treatment."( Long-term prophylactic treatment of attacks of vertigo in Menière's disease--comparison of a high with a low dosage of betahistine in an open trial.
Brandt, T; Frenzel, C; Hahn, A; Hupert, D; Jahn, K; Mansmann, U; Strupp, M; Wagner, J; Zingler, VC, 2008
)
0.76
"To evaluate the prophylactic effects of a low versus high dosage long-term treatment with betahistine-dihydrochloride on the number of attacks in MD."( Long-term prophylactic treatment of attacks of vertigo in Menière's disease--comparison of a high with a low dosage of betahistine in an open trial.
Brandt, T; Frenzel, C; Hahn, A; Hupert, D; Jahn, K; Mansmann, U; Strupp, M; Wagner, J; Zingler, VC, 2008
)
0.78
"We performed an open, non-masked trial, in which patients with MD received either a low dosage of betahistine-dihydrochloride (16 or 24 mg tid) or a higher dosage of 48 mg tid for at least 12 months."( Long-term prophylactic treatment of attacks of vertigo in Menière's disease--comparison of a high with a low dosage of betahistine in an open trial.
Brandt, T; Frenzel, C; Hahn, A; Hupert, D; Jahn, K; Mansmann, U; Strupp, M; Wagner, J; Zingler, VC, 2008
)
0.77
"A total of 112 patients were included in the analysis: 50 received betahistine-dihydrochloride in a low dosage (16 mg tid, n=21, 24 mg, n=29) and 62 received 48 mg tid."( Long-term prophylactic treatment of attacks of vertigo in Menière's disease--comparison of a high with a low dosage of betahistine in an open trial.
Brandt, T; Frenzel, C; Hahn, A; Hupert, D; Jahn, K; Mansmann, U; Strupp, M; Wagner, J; Zingler, VC, 2008
)
0.79
" There was no significant difference between dosage groups regarding improvement in vertigo at any time point during the study."( Comparable efficacy and tolerability between twice daily and three times daily betahistine for Ménière's disease.
Caovilla, HH; Ganança, FF; Ganança, MM, 2009
)
0.58
" In this case series 11 patients with MD who had not responded sufficiently to a dosage of 144 mg/day of betahistine dihydrochloride were treated on an individual basis with daily dosages between 288 and 480 mg of betahistine dihydrochloride."( High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Menière's disease: a case series.
Adrion, C; Jahn, K; Lezius, F; Mansmann, U; Strupp, M, 2011
)
0.96
" The intensity, frequency and duration of tinnitus were assessed on the first day of dosing and after 120 days of treatment."( Betahistine in the treatment of tinnitus in patients with vestibular disorders.
Caovilla, HH; Ganança, CF; Ganança, FF; Ganança, MM; Gazzola, JM,
)
1.57
"The daily dosage of 48 mg of betahistine during 120 consecutive days is useful to reduce or eliminate tinnitus in patients with vestibular disorders."( Betahistine in the treatment of tinnitus in patients with vestibular disorders.
Caovilla, HH; Ganança, CF; Ganança, FF; Ganança, MM; Gazzola, JM,
)
1.87
" The effects of the dosage range of betahistine on cochlear microcirculation corresponded well to clinically used single dosages to treat Menière's disease."( Betahistine exerts a dose-dependent effect on cochlear stria vascularis blood flow in guinea pigs in vivo.
Bertlich, M; Canis, M; Ihler, F; Sharaf, K; Strieth, S; Strupp, M, 2012
)
2.1
" Possible explanations are: (1) insufficient dosage or duration of treatment with betahistine, (2) insufficient resolution of the MR imaging technique, and (3) insufficient length of follow-up."( Effect of standard-dose Betahistine on endolymphatic hydrops: an MRI pilot study.
Ertl-Wagner, B; Flatz, W; Gürkov, R; Keeser, D; Krause, E; Strupp, M, 2013
)
0.92
" A total of 113 medical records were analysed; 53 patients received betahistine-dihydrochloride at on-label dosage (32 mg die) for six months, and 60 patients were treated with the same regimen and nimodipine (40 mg die) as an add-therapy during the same period."( Effect of a fixed combination of nimodipine and betahistine versus betahistine as monotherapy in the long-term treatment of Ménière's disease: a 10-year experience.
Aggazzotti Cavazza, E; Alicandri Ciufelli, M; Barillari, MR; Genovese, E; Monzani, D; Neri, V; Presutti, L, 2012
)
0.87
"The aim of the present study was to assess if the combined therapy of intratympanic dexamethasone (ITD) and high dosage of betahistine (HDBH) is able to provide increased vertigo control compared to ITD alone in patients suffering from definite unilateral Meniere's disease (MD)."( Treatment of Meniere's disease with intratympanic dexamethazone plus high dosage of betahistine.
Albu, S; Cozma, S; Doros, C; Marceanu, L; Musat, G; Nagy, A; Trabalzini, F,
)
0.56
" 99%), metabolized by monoamine oxidases (MAO), the benefits of a high-dosage betahistine monotherapy were compared with those of a lower dosage of betahistine in combination with the MAO-B inhibitor (MAO-B) selegiline on the frequency of acute attacks of vertigo in patients with Menière's disease (MD)."( Menière's disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline-an observational study.
Kraus, L; Rujescu, D; Schautzer, F; Strupp, M, 2018
)
0.96
"9 years; six females) had initially been treated with a high dosage of betahistine dihydrochloride for at least 1 year."( Menière's disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline-an observational study.
Kraus, L; Rujescu, D; Schautzer, F; Strupp, M, 2018
)
0.97
"The initial dosage for the long-term "titration" of the attacks of vertigo was 9-80 24-mg tablets/day (mean 37."( Menière's disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline-an observational study.
Kraus, L; Rujescu, D; Schautzer, F; Strupp, M, 2018
)
0.74
"The achievement of the same clinical effect with a significantly lower (about 1/5) dosage of betahistine can be explained by the inhibition of the MAO-B by selegiline leading to higher serum concentrations of betahistine."( Menière's disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline-an observational study.
Kraus, L; Rujescu, D; Schautzer, F; Strupp, M, 2018
)
0.95
"Orodispersible film (ODF) is a widely used oral solid dosage form."( Effect of drug-ion exchange resin complex in betahistine hydrochloride orodispersible film on sustained release, taste masking and hygroscopicity reduction.
Fang, L; Liu, C; Quan, P; Shang, R; Zhao, H, 2018
)
0.74
"Objects of research are solid dosage forms (tablets) containing betahistine in a dose of 24 mg permitted for medical use in the Russian Federation."( [In vitro equivalence evaluation of betahistine generic medicinal products as a tool potentially determining the efficacy of pharmacotherapy].
Butranova, OI; Gildeeva, GN; Ramenskaya, GV; Shohin, IE; Zyryanov, SK,
)
0.64
"To achieve both hearing preservation and vertigo control, the best treatment option among the pharmacologic interventions compared may be IT steroid plus high-dose betahistine, considering that IT gentamicin may have good performance to control vertigo but may be detrimental to hearing preservation with high cumulative dosage and short interval between injections."( Pharmacologic and surgical therapies for patients with Meniere's disease: A systematic review and network meta-analysis.
Ahmadzai, N; Bonaparte, J; Cheng, W; Esmaeilisaraji, L; Fitzpatrick, E; Hutton, B; Kilty, S; Lin, V; Schramm, D; Skidmore, B; Wolfe, D, 2020
)
0.75
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
vasodilator agentA drug used to cause dilation of the blood vessels.
H1-receptor agonistA histamine agonist that binds to and activates H1-receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
aminoalkylpyridine
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Betahistine H1-Antihistamine Action87

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histamine H3 receptorRattus norvegicus (Norway rat)Ki2.03000.00010.29638.5110AID375699
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID86750Contractile effect on isolated guinea pig ileal segments is a measure of H1 (histamine) receptor agonistic activity relative to histamine.1995Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8
Synthesis and histamine H1 receptor agonist activity of a series of 2-phenylhistamines, 2-heteroarylhistamines, and analogues.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID375699Binding affinity to rat histamine H3 receptor2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
5-hydroxyindole-2-carboxylic acid amides: novel histamine-3 receptor inverse agonists for the treatment of obesity.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (420)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990107 (25.48)18.7374
1990's43 (10.24)18.2507
2000's105 (25.00)29.6817
2010's120 (28.57)24.3611
2020's45 (10.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 114.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index114.65 (24.57)
Research Supply Index6.38 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index211.95 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (114.65)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials127 (27.67%)5.53%
Reviews50 (10.89%)6.00%
Case Studies22 (4.79%)4.05%
Observational2 (0.44%)0.25%
Other258 (56.21%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (19)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
"Pharmacokinetic Profile of Betahistine Serum Concentration With and Without Selegiline in Healthy Volunteers - a Prospective Mono-center Open-labeled Phase I Trial (PK-BeST)" [NCT05938517]Phase 115 participants (Actual)Interventional2021-06-02Completed
Evaluation of Safety, Drug-Drug Interactions and Pharmacokinetic Profiles of Co-Administration of Escalating Doses of Extended Release and Standard Formulations of Betahistine as Monotherapy and as Adjunctive to Olanzapine in Healthy Subjects [NCT01168336]Phase 190 participants (Anticipated)Interventional2010-07-31Completed
The Attenuation of Second Generation Antipsychotic Induced Weight Gain in Adolescents and Adults Using Betahistine: A Double-Blind, Placebo-Controlled Trial [NCT00709202]Phase 248 participants (Actual)Interventional2008-07-31Completed
The Effect of Vestibular Exercise, With or Without Medication, in Managing Residual Dizziness After Successful Repositioning Maneuvers in Patients With Benign Paroxysmal Positional Vertigo [NCT03624283]183 participants (Anticipated)Interventional2018-09-01Recruiting
Effect of Modified Epley's & Semont's Maneuvers With or Without Beta-histine on Benign Paroxysmal Positional Vertigo: A Randomized Control Trail [NCT05309538]90 participants (Actual)Interventional2021-01-02Completed
Effect of Head Acupuncture on Residual Symptoms After Canalith Repositioning Procedure for Benign Paroxysmal Positional Vertigo: a Single-center Randomized Controlled Trial. [NCT06001047]120 participants (Anticipated)Interventional2023-11-01Recruiting
A Double-Blind, Placebo-Controlled, Randomized, Clinical Study of the Effects of Betaserc® 24 mg (1 Tablet b.i.d Over 3 Months) on Vestibular Compensation Following Vestibular Neurotomy in Patients With Disabling Menière's Disease [NCT00160238]Phase 420 participants Interventional2003-01-31Completed
A Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features [NCT00585585]Phase 21 participants (Actual)Interventional2007-07-31Terminated(stopped due to Lack of participants)
A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effect of Betahistine on Plasma Lipids in Patients Treated With Simvastatin [NCT00466869]Phase 230 participants (Anticipated)Interventional2007-05-31Terminated(stopped due to Sponsor decision)
Betahistine: Novel Therapeutic in Attention Deficit Hyperactivity Disorder [NCT00829881]Phase 116 participants (Actual)Interventional2009-01-31Completed
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Betahistine on Body Weight in Obese Female Subjects [NCT00748436]Phase 2187 participants (Actual)Interventional2008-09-30Completed
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Betahistine on Body Weight in Obese Subjects [NCT00409305]Phase 2280 participants Interventional2007-01-31Completed
[NCT02026778]168 participants (Actual)Interventional2013-12-31Completed
Evaluation of Safety, Drug-Drug Interactions and Pharmacokinetic Profiles of Co-Administration of Betahistine With Olanzapine in Healthy Female Subjects [NCT00852956]Phase 150 participants (Anticipated)Interventional2009-02-28Completed
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine Treatment [NCT00428168]Phase 236 participants (Actual)Interventional2007-03-31Terminated(stopped due to Interim Analysis result indicated the study will not show a significant benefit of the study medication on the primary endpoint.)
Pilot Study of the Metabolic Effects of Betahistine Hydrochloride in Overweight Women [NCT00459992]Phase 1150 participants (Actual)Interventional2007-04-10Completed
Pilot Study of Modulating Auditory Symptoms and Vertigo of Meniere's Disease by Non-invasive Mastoid Electric Stimulation: Double-blind, Randomized, Sham-controlled, Investigator-initiated Trial [NCT06001593]Phase 1/Phase 2120 participants (Anticipated)Interventional2023-09-07Recruiting
A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Effect of Betahistine on Cerebral Blood Flow and Gait in Subjects at Risk of Falling [NCT01468285]Phase 427 participants (Actual)Interventional2012-02-29Completed
Transcutaneous Auricular Vagus Nerve Stimulation for Meniere Disease: Randomized Trial Controlled [NCT05328895]92 participants (Actual)Interventional2020-10-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00709202 (11) [back to overview]Change in Appetite Fullness
NCT00709202 (11) [back to overview]Change in Appetite Hunger
NCT00709202 (11) [back to overview]Change in Body Mass Index (BMI)
NCT00709202 (11) [back to overview]Change in Cholesterol
NCT00709202 (11) [back to overview]Change in Glucose
NCT00709202 (11) [back to overview]Change in HDL
NCT00709202 (11) [back to overview]Change in Hip Circumference
NCT00709202 (11) [back to overview]Change in LDL
NCT00709202 (11) [back to overview]Change in Triglycerides
NCT00709202 (11) [back to overview]Change in Waist Circumference
NCT00709202 (11) [back to overview]Change in Weight

Change in Appetite Fullness

"Least Squares estimated change in appetite fullness from end of study minus baseline.The scale used has no specific name. It is a Visual Analogue Scale, where a line is drawn of 10 cm long with the statement beneath the line How full do you feel '. The subject places an X on the line. The measurements, the number of centimeters from the start of the line (O). indicate amount of feeling of fullness. The higher the cm number the higher the feeling of fullness. The measure reported is the difference in this scale reading in cm from after the test meal to before consuming the test meal. The number (mean, s.e.m.) presented is the analysis of covariance model estimated difference score at the end of study, with the covariate of the same score at baseline." (NCT00709202)
Timeframe: .Measured at baseline and 12 weeks

Interventionunits on a scale (Least Squares Mean)
Betahistine1.800
Placebo4.698

[back to top]

Change in Appetite Hunger

"Least Squares estimated change in appetite hunger from end of study minus baseline.The scale used has no specific name. It is a Visual Analogue Scale, where a line is drawn of 10 cm long with the statement beneath the line How Hungry do you feel '. The subject places an X on the line. The measurements, the number of centimeters from the start of the line (O), indicate the amount of hunger. The higher the cm number the higher the feeling of hunger. The measure reported is the difference in this scale reading in cm from after the test meal to before consuming the test meal. The number (mean, s.e.m) presented is the analysis of covariance model estimated difference score at the end of study, with the covariate of the same score at baseline." (NCT00709202)
Timeframe: Measured at baseline and 12 weeks

Interventionunits on a scale (Least Squares Mean)
Betahistine-3.605
Placebo-3.684

[back to top]

Change in Body Mass Index (BMI)

Least Squares estimated change in BMI from end of study minus baseline (NCT00709202)
Timeframe: Measured at each visit from baseline to end of study over a 12 week period.

Interventionkg/m^2 (Least Squares Mean)
Betahistine-0.5524
Placebo-0.5637

[back to top]

Change in Cholesterol

Least Squares estimated change in cholesterol from end of study minus baseline (NCT00709202)
Timeframe: Measured at each visit from baseline to end of study over a 12 week period.

Interventionmg/dL (Least Squares Mean)
Betahistine1.087
Placebo1.010

[back to top]

Change in Glucose

Least Squares estimated change in glucose from end of study minus baseline (NCT00709202)
Timeframe: Measured at each visit from baseline to end of study over a 12 week period.

Interventionmg/dL (Least Squares Mean)
Betahistine4.292
Placebo3.136

[back to top]

Change in HDL

Least Squares estimated change in HDL from end of study minus baseline (NCT00709202)
Timeframe: Measured at each visit from baseline to end of study over a 12 week period.

Interventionmg/dL (Least Squares Mean)
Betahistine2.555
Placebo-0.840

[back to top]

Change in Hip Circumference

Least Squares estimated change in hip circumference from end of study minus baseline (NCT00709202)
Timeframe: Measured at each visit from baseline to end of study over a 12 week period.

Interventioncentimeters (Least Squares Mean)
Betahistine1.7957
Placebo1.3668

[back to top]

Change in LDL

Least Squares estimated change in LDL from end of study minus baseline (NCT00709202)
Timeframe: Measured at each visit from baseline to end of study over a 12 week period.

Interventionmg/dL (Least Squares Mean)
Betahistine1.799
Placebo0.915

[back to top]

Change in Triglycerides

Least Squares estimated change in triglycerides from end of study minus baseline (NCT00709202)
Timeframe: Measured at each visit from baseline to end of study over a 12 week period.

Interventionmg/dL (Least Squares Mean)
Betahistine-4.426
Placebo-3.360

[back to top]

Change in Waist Circumference

Least Squares estimated change in waist circumference from end of study minus baseline (NCT00709202)
Timeframe: Measured at each visit from baseline to end of study over a 12 week period.

Interventioncentimeters (Least Squares Mean)
Betahistine4.0928
Placebo2.4864

[back to top]

Change in Weight

Least Squares estimated change in weight from end of study minus baseline (NCT00709202)
Timeframe: Measured at each visit from baseline to end of study over a 12 week period

Interventionkg. (killograms) (Least Squares Mean)
Betahistine-2.0021
Placebo-1.5490

[back to top]